> ## Content Index
> Fetch the complete content index at: https://members.americanhealthintel.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Curium to acquire Lantheus for up to $8B
- URL: https://members.americanhealthintel.com/2026-08-03-ledger/
- Published: 2026-08-03T15:59:11.000Z
- Updated: 2026-08-03T15:59:11.000Z
- Description: Plus: Supernus and Indivior merge as equals into $2.2B CNS drugmaker. The day's rules, money, and enforcement, sourced and tiered below.
- Author: American Health Intel

Plus: Supernus and Indivior merge as equals into $2.2B CNS drugmaker. The day's rules, money, and enforcement, sourced and tiered below.

| American Health Intel Rules · Money · Medicine · Decoded daily The Ledger Monday, August 3, 2026 Curium to acquire Lantheus for up to $8B Plus: Supernus and Indivior merge as equals into $2.2B CNS drugmaker. The day's rules, money, and enforcement, sourced and tiered below. ![](https://americanhealthintel.com/email/pulse-divider.png) Deal Confidence: High Curium, a global radiopharmaceutical maker, is paying up to 8 billion dollars to acquire Lantheus, the US market leader in radioactive imaging drugs used to find and monitor prostate cancer and heart disease. The deal pays 102.50 dollars a share in cash plus up to 12 dollars more tied to sales targets through 2030, a 38% premium, and combines two of nuclear medicine's largest manufacturers. Why it matters Two of the world's largest makers of radioactive imaging and treatment drugs are combining, a bet that pairing diagnosis and treatment in one company, called theranostics, is the future of nuclear medicine. Watch whether the combined company changes access or pricing for scans used in prostate cancer and heart disease. Sources: [Globenewswire](https://www.globenewswire.com/news-release/2026/08/03/3337411/0/en/Curium-Announces-Definitive-Agreement-to-Merge-with-Lantheus.html?ref=members.americanhealthintel.com) · [SEC](https://www.sec.gov/Archives/edgar/data/0001521036/000119312526210369/lnth-ex99%5F1.htm?ref=members.americanhealthintel.com) Deal Confidence: High Supernus and Indivior, two central-nervous-system drugmakers, one known for ADHD and epilepsy medicines and the other for opioid-addiction treatments, are merging as equals to create a 2.2 billion dollar drug company. Indivior shareholders get 56.5% of the combined company plus a 1 billion dollar cash payout before closing. Supernus CEO Jack Khattar leads the new company, expected to close in Q4 2026. Why it matters Two central-nervous-system drugmakers, one known for ADHD and epilepsy medicines and the other for opioid-addiction treatment, are combining into an 11-medicine company. Watch whether the combined company changes access, marketing, or pricing for these drugs. Sources: [Globenewswire](https://www.globenewswire.com/news-release/2026/08/03/3337311/19871/en/Supernus-Pharmaceuticals-and-Indivior-Pharmaceuticals-to-Merge-Creating-a-Diversified-CNS-Biopharmaceutical-Leader-with-Significant-Scale.html?ref=members.americanhealthintel.com) Also today Alignment Healthcare beats guidance, membership up 31%, shares fall [Read](https://americanhealthintel.com/editions/2026-08-03-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#alignment-healthcare-q2-2026-earnings-membership-growth) Healthcare Realty Trust grows same-store NOI 5.1%, raises guidance [Read](https://americanhealthintel.com/editions/2026-08-03-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition#healthcare-realty-trust-q2-2026-mob-reit-earnings) 374Records$31.6BEnforcement17Deadlines110Rules [Read this issue + the trackers](https://americanhealthintel.com/editions/2026-08-03-ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) Pick your field on the site and every story tells you what it means for you. Reply to this email and tell us what you want covered. We read everything. We show our work. We score our own calls. [Track record](https://americanhealthintel.com/ledger/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Calendar](https://americanhealthintel.com/calendar/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [Enforcement](https://americanhealthintel.com/enforcement/?utm%5Fsource=newsletter&utm%5Fmedium=email&utm%5Fcampaign=edition) · [X](https://x.com/amhealthintel?ref=members.americanhealthintel.com) · [LinkedIn](https://www.linkedin.com/company/american-health-intel?ref=members.americanhealthintel.com) News and analysis, not legal, medical, coding, or investment advice.You subscribed at americanhealthintel.com · [Unsubscribe](%%{unsubscribe%5Furl}%%) |
| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |